Mallinckrodt boosts specialty pharma unit with $1.3B Cadence buy

02/11/2014 | Genetic Engineering & Biotechnology News · Reuters

Cadence Pharmaceuticals, the maker of pain and fever drug Ofirmev, will be purchased by Mallinckrodt Pharmaceuticals for around $1.3 billion, or $14 per share. Mallinckrodt said the deal would expand its portfolio of specialty pharmaceutical products and extend its reach into the hospital market, where many Cadence products are used. The deal, expected to be finalized in March, "is consistent with our goal of becoming a leading global specialty pharmaceuticals company," Mallinckrodt CEO and President Mark Trudeau said.

View Full Article in:

Genetic Engineering & Biotechnology News · Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ